Article info
PDFExtended essay
Reconceptualising risk–benefit analyses: the case of HIV cure research
- Correspondence to Dr Robert Steel, Clinical Center Department of Bioethics, National Institutes of Health, Bethesda, MD 20892, USA; pirateofthecaribbean{at}gmail.com
Citation
Reconceptualising risk–benefit analyses: the case of HIV cure research
Publication history
- Received April 30, 2019
- Revised July 25, 2019
- Accepted October 8, 2019
- First published November 15, 2019.
Online issue publication
February 21, 2020
Article Versions
- Previous version (21 February 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Traditional healers, faith healers and medical practitioners: the contribution of medical pluralism to bottlenecks along the cascade of care for HIV/AIDS in Eastern and Southern Africa
- ‘Side effects’ are ‘central effects’ that challenge retention in HIV treatment programmes in six sub-Saharan African countries: a multicountry qualitative study
- Factors associated with attitudes towards HIV cure research among transgender women and travestis: a cross-sectional survey in São Paulo, Brazil
- Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes
- ‘Staying alive’ with antiretroviral therapy: a grounded theory study of people living with HIV in Peru
- Understanding the relationship between couple dynamics and engagement with HIV care services: insights from a qualitative study in Eastern and Southern Africa
- For love and money: the need to rethink benefits in HIV cure studies
- Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000–2018
- Mitigating the effects of COVID-19 on HIV treatment and care in Lusaka, Zambia: a before–after cohort study using mixed effects regression
- Can we talk about price with patients when choosing antiretroviral therapy? A survey with people living with HIV and prescribers in France